Julphar Pharmaceuticals PLC

Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa, delivering high-quality, innovative, and affordable healthcare solutions globally. It is the only pharmaceutical company in the region manufacturing a full range of biosimilar insulin analogues, advancing regional self-sufficiency and access to advanced diabetes therapies.

History & Origins

• Established: 1980 under the guidance of Sheikh Saqr Bin Mohammed Al Qasimi, the late Ruler of Ras Al Khaimah.
• Industry Experience: Over four decades of operational and pharmaceutical manufacturing expertise.
• Global Headquarters: Ras Al Khaimah, United Arab Emirates.

Manufacturing Capacity & Operational Scale

• Workforce: Employs approximately 2,500 people.
• Global Footprint: Distributes medicines to more than 40 countries across five continents.
• Production Infrastructure: Operates 10 internationally accredited manufacturing facilities.
• Daily Output: Combined production capacity of up to one million packs of medicine per day.

Therapeutic Areas & Portfolio

Julphar produces general medicines and specialty products for hospital and retail pharmacy channels across key therapeutic fields:

• Advanced Diabetes Care: Specialized manufacturing of biosimilar insulin analogues.
• General & Specialty Medicine:
• Gastrointestinal disorders
• Respiratory care
• Pain management
• Wound and scar care
• Anti-infectives
• Anemia
• Gynecology
• Dermatology
• Cardiology